Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Oryzon Genomics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ORYZON Presents vafidemstat 12-month Clinical Data From its Phase IIa Trials ETHERAL and REIMAGINE-AD in Alzheimer’s

Details:

By modulating the histone modifying enzyme LSD1, vafidemstat has been shown to have potential in Alzheimer’s and a range of other CNS diseases.

Lead Product(s): Vafidemstat

Therapeutic Area: Neurology Product Name: ORY-2001

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2021

ASK
US

Upload
your Pipeline Activity

Oryzon Genomics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer’s Disease

Details:

REIMAGINE-AD is a Phase IIa study to assess the effect of vafidemstat in agitation-aggression in moderate and severe AD patients.

Lead Product(s): Vafidemstat

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY